Aligos Therapeutics, Inc. Income Statement
ALGS|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Aligos Therapeutics, Inc. reported $2M in revenue and $24M in net loss for FY2025. Revenue has declined at a 40.6% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 | $0 |
| SG&A Expense | $20.7M | $22.8M | $26.4M | $28.5M | $17.9M | $10.0M |
| R&D Expense | $69.5M | $70.3M | $85.1M | $104.2M | $79.9M | $44.0M |
| Operating Income | -$88.0M | -$89.2M | -$97.6M | -$128.3M | -$97.8M | -$54.0M |
| Interest Expense | - | - | $1.5M | - | - | - |
| Income Tax | $314.0K | $331.0K | $106.0K | $143.0K | $161.0K | $85.0K |
| Net Income | -$24.2M | -$131.2M | -$96.0M | -$128.3M | -$108.5M | -$52.3M |
| EPS (Basic) | -$20.94 | -$34.20 | -$2.25 | - | - | - |
| EPS (Diluted) | -$20.94 | -$34.20 | -$2.25 | -$3.22 | -$10.87 | -$26.04 |
| Shares Outstanding | 79.9M | 3.0M | 42.9M | 42.7M | 38.1M | 3.9M |
| Operating Margin | -4024.9% | -2469.0% | -1576.2% | - | - | - |
| Profit Margin | -1106.7% | -3633.7% | -1551.4% | - | - | - |